Screener
Vera Therapeutics VERA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $86,011 | $41,278 |
| General and administrative | 39,121 | 15,916 |
| Total operating expenses | 125,132 | 57,194 |
| Loss from operations | (125,132) | (57,194) |
| Other income (expense): | ||
| Interest income | 6,355 | 6,906 |
| Interest expense | (1,823) | (1,792) |
| Other (expense) income, net | (432) | 386 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's operating income?
- Vera Therapeutics (VERA) reported operating income of -$125.13M in Q1 2026.
- How has Vera Therapeutics's operating income changed year-over-year?
- Vera Therapeutics's operating income decreased by 118.8% year-over-year, from -$57.19M to -$125.13M.
- What is the long-term trend for Vera Therapeutics's operating income?
- Over 4 years (2021 to 2025), Vera Therapeutics's operating income has grown at a 74.0% compound annual growth rate (CAGR), from -$34.4M to -$315.47M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Vera Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude